Colorado woman runs 189 miles to raise awareness about multiple sclerosis
While a lot of people are relaxing on Memorial Day weekend, one Colorado woman is spending her week raising awareness about Multiple Sclerosis by running further than some people will run in their lives.
Megan Gage is thankful for every step she takes, and this week she will be taking a lot of them.
"I've trained for a long time, and I'm excited that it's finally here," said Gage. "The goal is to save some of the energy by giving less than I'm capable of, so that over the course of a week, I have gas left in the tank."
The Castle Rock woman is running 189 miles from Denver's Sloan Lake to the Colorado-Nebraska state line. By 6 am on Sunday, she already had four under her belt, and she says she feels good.
"Last night I felt calm. The night before that, I was a mess," said Gage.
She is on this journey to raise money for and awareness about multiple sclerosis and multiple sclerosis research. A cause that is important to her because five years ago she was diagnosed with the disease.
"My future turned gray where it's like all the color is instantly sucked out," said Gage.
Initially, she was frightened because the autoimmune disease had the potential to strip her of all her movement and lead to her eventual death. But after running a half marathon shortly after diagnosis, she decided to take her health into her own hands as much as possible.
Megan Gage sits in a hospital bed after being diagnosed with multiple sclerosis.
Megan Gage
She started running and eventually joined Team MS Run the US on their annual run across the United States. This week, she is running her leg of the cross-country effort.
She's been training for months now, but even that hasn't been without challenges. Just a few weeks ago, she came down with COVID, which is a little more difficult for her.
"One of the main treatments for MS compromises your immune system and when you don't have any B-cells, it makes it much harder to fight off basic things like COVID," said Gage. "But I missed one run in seven months. So, I think that I showed up enough that I think I'm going to be okay."
She is making her way to Wray, Colorado to prove to herself and her community that with the right attitude and support, you can overcome anything.
Megan Gage celebrates finishing a race. The Colorado woman is now running 189 miles to raise money and awareness about multiple sclerosis.
Megan Gage
"My people have shown up. They've donated. They've supported, you know, bracelets and bumblebees and just little mementos to know that I have my people with me. It's meant everything," said Gage.
She'll finish her leg in seven days, and she's hoping to reach her 15,000 fundraising goal by then.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
Denver Health partners with Flight for Life to provide critical care transport
Denver Health is launching a new partnership that they said will save lives. A bright orange helicopter will now be stationed at Denver Health on the first Thursday of each month. It's one of the aircraft that belongs to Flight for Life, a critical care transport company the hospital said is known for its state-of-the-art fleet and experienced medical teams. CBS Dr. Gene Moore, a surgeon at Denver Health, said traffic can often keep regular ambulances from reaching patients in a timely manner. "Furthermore, I think we have learned more and more, particularly with our war experience in Iraq and Afghanistan, that survival is based on care to the patient as soon as possible," said Moore. Flight for Life is one of several air ambulance services that work with Denver Health.
CBS News
3 hours ago
- CBS News
Man biking to all 92 Dunkin' locations in Boston to raise money for multiple sclerosis research
Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis Man riding bike to all the Dunkin' locations in Boston to raise money for multiple sclerosis A Cambridge man spent National Donut Day biking to every Dunkin' in Boston to raise money for multiple sclerosis research. Adam Bigelow planned to eat one Munchkin at all of the 92 Dunkin' locations. He decided to do this ride to honor his girlfriend, who was diagnosed with MS last summer. He has raised more than $5,000 for a charity bike ride to the tip of Cape Cod with the Multiple Sclerosis Society later this month. "I thought it would be really fun and very Boston to go to every single Dunkin' and raise awareness about why I'm doing this," Bigelow told WBZ-TV. He began his journey at 4:30 a.m. Friday in East Boston and planned to end it in Allston-Brighton. "Outpouring of support" "All the Dunkin employees have been holding these signs and cheering me on; that outpouring of support really keeps me going. It's been a ton of fun so far," Bigelow said. "It's so cool to see that everybody has been banding together behind me to help make this happen." The company heard about his story and gave Bigelow more than 200 gift cards to give out along the way. He said the company also gave him special swag to hand out to some people who donate to his fundraising page. "It's so great that our location is part of Adam's journey," said Dunkin' store manager Richter Racine. "It makes me and her [his girlfriend] feel very supported in all this, especially the messages from other people who have had challenges with this disease, who have been reaching out. That's really special and makes me feel like, you know, it's such a great cause," Bigelow said. Follow the bike ride on National Donut Day You can track Bigelow's route on his Instagram page and possibly snag a gift card from him alongside a free donut with any drink purchase at Dunkin' for National Donut Day.
Medscape
4 hours ago
- Medscape
Experimental MS Drug Nearly Eliminates Disease Activity
PHOENIX — Frexalimab, a second-generation anti-CD40 ligand monoclonal antibody provides extended tight control of multiple sclerosis (MS) whether measured by relapse or brain imaging at 2-year follow-up, results of an open-label extension (OLE) of a phase 2 trial showed. 'At week 96, there was almost complete suppression of new gadolinium-enhancing lesions with very similar pattern seen with new or enhancing T2 lesions,' said study investigator Stephen Krieger, MD, professor of neurology, Icahn School of Medicine at Mount Sinai, New York City. Two phase 3 international studies with this drug are already enrolling. 'Part of the interest in frexalimab and anti-CD40 therapies is the idea that one can modulate both B- and T-cell activity without cell depletion,' explained Krieger, who presented the long-term open-label data on May 29 at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting. Near Complete Disease Suppression The latest data suggest frexalimab is fulfilling its promise. Over follow-up to date, there has been nearly complete suppression of gadolinium-enhancing (Gd+) lesions on MRI among those taking the dose now being tested in the phase 3 trials. At 2 years, with an annualized relapse rate of 0.08%, 92% of patients were relapse-free. The randomized portion of this phase 2 trial attracted attention when it was published a year ago in The New England Journal of Medicine , but the 2-year results showed that the efficacy and safety observed at 12 weeks persist. In the controlled trial, 129 patients with relapsing MS were randomized to 300-mg, 400-mg, 600-mg, or 1200-mg frexalimab or matching placebos. Suppression of Gd+ lesions was the primary endpoint. At 12 weeks, the adjusted mean of new Gd+ lesions was 1.4 in the combined placebo groups but 0.3 in the 300-mg frexalimab group and 0.2 in the 1200-mg group. Of those who participated in the randomized portion of the phase 2 trial, 97% continued into the long-term OLE. The OLE consisted of two arms: 1200-mg frexalimab administered intravenously every 4 weeks or 300-mg frexalimab administered subcutaneously every 2 weeks. At the end of 2 years, when 82% of those enrolled in the OLE were still on medication, the adjusted mean for new T1-weighted Gd+ lesions ranged from 0.1 to 0.3 across study arms whether on continuous frexalimab or switched from placebo to frexalimab. For those who were initiated on the 1200-mg dose in the controlled portion of the trial and remained on this dose for the OLE, the mean was 0.1. For the secondary endpoint of new or enlarging T2 lesions, the suppression at 2 years was almost the same. Again, the adjusted mean for new lesions across all arms ranged from 0.1 to 0.3. For those receiving the 1200-mg dose, the mean was 0.2. Mean T2 lesion volume increased in the placebo arm but not in the treatment arms during the randomized phase. After entering the OLE, T2 lesion volume fell in placebo patients now on active therapy. In the 1200-mg arm, the fall in lesion volume during the randomized phase continued into the first 24 weeks of the OLE. After 24 weeks, the lesion volume remained suppressed with no return toward baseline. Those initiated on placebo never caught up after switching to frexalimab. Relapse Rare — 2% at 96 Weeks On the 1200-mg dose of frexalimab, only 8% had any relapse recorded over the extended follow-up. In half, there was a single relapse. Only 2% had three or more relapses. While the Expanded Disability Status Scale score declined slightly among placebo patients once started on active therapy, there was no change from baseline through 96 weeks in patients started on any active therapy. As postulated by earlier preclinical and clinical studies, frexalimab had no effect on lymphocyte counts over time. Over the 96-week follow-up, levels of immunoglobulins remained unchanged, according to Krieger who showed graphs with straight lines for these values over the course of the OLE. Due to the potential of suppressing activation of both T and B cells over time, anti-CD40 therapies have long been considered a promising mechanism for control of MS. However, clinical development of first-generation drugs was abandoned because of an association with thromboembolism. 'Frexalimab has been engineered to avoid these events through a change in the Fc receptors with reduces downstream inflammatory events,' said Krieger. The long-term data support this premise. Over 2 years, there was one pulmonary embolism, but this exception was observed in a patient with a viral illness and a genetic predisposition for an inflammatory response, according to Krieger. When surveying other adverse events, 'nothing jumps out' in the OLE relative to the randomized phase. One potential exception is a rise in liver function tests observed in two (4%) patients on the 1200-mg dose. Only one of these patients discontinued therapy, and the levels returned to normal over time in both. The effects of the anti-CD40 mechanism on both the adaptive and innate immune systems suggest frexalimab might offer efficacy for both progressive and relapsing MS. In the ongoing phase 3 program, one of the trials (FREXALT) is enrolling patients with relapsing MS. The other (FREVIVA) is enrolling patients with progressive disease. Fulfilling its Promise Commenting on the results, Amit Bar-Or, MD, Chief of the Multiple Sclerosis Division, the Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, described frexalimab as 'a very interesting drug.' He agreed that the CD40 ligand is a promising target in MS but cautioned that these phase 2 data cannot answer the most interesting questions. This includes the more robust evidence of safety and efficacy from phase 3 trials, but it remains unclear whether the benefits extend beyond controlling relapsing disease. 'I think there is particular interest in whether it will also show extended benefit in progressive MS, and this will be a major focus of interest from the next set of studies,' Bar-Or said.
